Now Reading: 137 cancer drugs capped at 30% trade margin from 9 Nov
-
01
137 cancer drugs capped at 30% trade margin from 9 Nov
The National Pharmaceutical Pricing Authority (NPPA), under the Department of Pharmaceuticals, has imposed a trade margin rationalisation (TMR) on 137 identified non-scheduled anti-cancer drugs, capping the margin at 30% of the maximum retail price (MRP). The move, notified in the gazette on 17 October 2026, is expected to cut MRPs by up to 70% on current prices, making cancer treatment more affordable.
The list was recommended by an expert committee under the Directorate General of Health Services (DGHS) comprising oncologists, medical experts and government officials. The current exercise expands on a 2019 pilot that capped margins on 42 cancer drugs, which later led to MRP reductions of up to 90% on 526 brands.
All manufacturers must report revised prices to NPPA within seven days of the gazette notification. The new prices take effect from 9 November 2026. Retailers and hospitals must sell at the lower rates from that date and display revised prices. State drug controllers will enforce compliance.
Indian Opinion Analysis
The price cap directly targets the high out-of-pocket expenditure that cancer patients face, particularly for non-scheduled drugs not already under price control. By fixing the trade margin at 30%, NPPA shifts the financial burden from patients to the supply chain. The effectiveness will depend on whether manufacturers maintain supply levels, as they are required to do. Hospitals that buy drugs directly must ensure the revised prices reach patients from 9 November 2026.
Source: pib.gov.in
This brief was synthesised by AI from the source linked above. Methodology and corrections.
